New launches take a back-seat due to lockdown. With an exception to Anti-Infective and Pain many other leading therapies grew in the June month resulting in IPM growth of 2.4%, after two months of consecutive decline. During the lockdown (April-June) phase, Cardiac and Anti-Diabetic were only two therapies that reported growth of 8.4% and 5.5% v/s IPM decline of 5.9%. The biggest beneficiaries here were Torrent pharma (7.4% Rx share in Cardiac), Lupin (9% and 7% Rx share in Anti-diabetic and Cardiac) and ERIS Life (56% of total revenue from Anti-Diabetic and Cardiac)....